All the news Showing 6 of 6 articles from: Interferon treatment for HBVGet an RSS feed of these articles Show All news infohep newsEditors' picks from other sources Using interferon with hepatitis B antivirals raises likelihood of HBsAg loss Liz Highleyman / 15 June 2015 Treating chronic hepatitis B with tenofovir plus pegylated interferon for 48 weeks resulted in a higher rate of hepatitis B surface antigen (HBsAg) clearance than either drug taken alone, though the response rate ... Adding pegylated interferon to tenofovir improves odds of HBsAg loss in hepatitis B patients Liz Highleyman / 05 February 2015 People with chronic hepatitis B virus (HBV) infection are more likely to experience favourable treatment response, as indicated by hepatitis B surface antigen (HBsAg) loss, if they add pegylated interferon to tenofovir – ... Adding interferon to nucleoside antivirals may improve response for people with chronic hepatitis B Liz Highleyman / 24 April 2014 Adding pegylated interferon to entecavir (Baraclude) led to greater hepatitis B virus (HBV) viral load decline and higher likelihood of serological response in people with HBeAg-positive chronic hepatitis B, as did added interferon after ... Prolonged pegylated interferon plus tenofovir does not prevent hepatitis delta relapse Liz Highleyman / 23 April 2014 Treating hepatitis B patients with hepatitis delta virus (HDV) co-infection using pegylated interferon plus tenofovir (Viread) for 96 weeks may reduce HDV viral load, but side-effects are frequent and it did not significantly improve ... Asian and Caucasian patients respond similarly to pegylated interferon for chronic hepatitis B Keith Alcorn / 20 May 2013 Some Asian people with chronic hepatitis B treated with pegylated interferon may experience better outcomes on certain measures than Caucasians, though overall response rates are similar, according to a comparative analysis presented at ... Adding pegylated interferon to entecavir improves hepatitis B treatment response Liz Highleyman / 13 December 2012 Intensifying entecavir (Baraclude) treatment for hepatitis B by adding pegylated interferon lowers HBV viral load and increases the likelihood of hepatitis B "e" antigen (HBeAg) loss, according to a presentation at The ... ← First1Next → Other pages in this section Latest news All the news Hepatitis A Hepatitis B Hepatitis C Hepatitis D Hepatitis E Coronavirus NAFLD Treatment for hepatocellular carcinoma Transmission, epidemiology and prevention Health services, policy and advocacy Social issues Conference news Email bulletin archive